肾盂输尿管癌多药耐药与蛋白激酶C的相关性研究  

Relationship between protein kinase C expression and multidrug resistance phenotype in renal pelvic and ureteral carcinoma

作　　者：孔垂泽[1] 李泽良[1] 杨涛[1] 刘同才[1] 张铭铮[1] 李书章[1] 王玉琳 

机构地区：[1]中国医科大学第一临床学院泌尿外科,沈阳110001 [2]辽宁省盘锦市第二医院外科

出　　处：《中华实验外科杂志》2001年第3期245-246,共2页Chinese Journal of Experimental Surgery

摘　　要：目的　探讨蛋白激酶C与肾盂输尿管癌多药耐药 (MDR)的相关性。方法　采用免疫组织化学卵白素生物素过氧化物酶连接法 (SABC)对 45例肾盂输尿管癌蛋白激酶C(PKC)、多药耐药膜糖蛋白表达进行对比研究。结果　肾盂输尿管癌蛋白激酶C阳性表达率为 60 .0 % (2 7/45 ) ,多药耐药膜糖蛋白阳性表达率为 62 .2 % (2 8/ 45 )。肾盂输尿管癌蛋白激酶C、多药耐药膜糖蛋白表达T2 ～T3 期与T1期、G2 ～G3 与G1级比较 ,差异有显著性 (P <0 .0 5 )。肾盂输尿管癌蛋白激酶C、多药耐药膜糖蛋白表达密切相关 (P <0 .0 5 )。结论　蛋白激酶C与肾盂输尿管癌多药耐药密切相关 。Objective To study the relationship between protein kinase C (PKC)expression and multidrug resistance phenotype in renal pelvic and ureteral carcinoma. Methods The expression of PKC and MDR PGP was detected by using immunohistochemical SABC method in 45 cases of renal pelvic and ureteral carcinoma. Results The positive rate for PKC and MDR PGP was 60.0% (27/45) and 62.2% (28/45) in renal pelvic and ureteral carcinoma respectively. There was statistically significant difference in PKC, MDR PGP expression between T 1 and T 2 to T 3 or G 1 and G 2 to G 3. After operation, the occurrence of bladder cancer was higher in MDR PGP positive group than in MDR PGP negative group (P<0.05). There was a close relationship between PKC and MDR PGP expression (P< 0.05). Conclusion PKC expression was closely related to multidrug resistance phenotype. PKC is probably an important modulator in adjusting MDR expression in renal pelvic and ureteral carcinoma.

关 键 词：肾盂癌 输尿管癌 蛋白激酶C 多药耐药性 

分 类 号：R737.13[医药卫生—肿瘤]